Table 1 Tumor specimens evaluated with DLL3 immunohistochemistry
From: Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
Organ site | Tumor type | Total cases (n) | Positive > = +1 n (%) | Total H-score median (range) | Membrane H-score median (range) |
|---|---|---|---|---|---|
Lung | |||||
|  | SCLC | 17 | 16 (94%) | 95 (0–175) | 20(0–70) |
LCNEC | 20 | 16 (80%) | 100 (0–180) | 20(0–115) | |
Mixed histology | 8 | 5 (63%) | 90 (0–175) | 35 (0–75) | |
Uterine cervix | |||||
|  | SCNEC | 10 | 9 (90%) | 137.5 (0-190) | 25 (0–42) |
LCNEC | 4 | 4 (100%) | 58.5 (0–115) | 11.5 (0–65) | |
Combined | 7 | 5 (71%) | 25 (0-185) | 6 (0–90) | |
Bladder | |||||
|  | SCC | 19 | 14 (74%) | 70 (0-210) | 0 (0–80) |
Skin | |||||
|  | Merkel cell carcinoma | 33 | 32 (97%) | 140 (0-190) | 26(0–70) |
Thyroid | |||||
|  | Medullary thyroid carcinoma | 74 | 20 (27%) | 0 (0–235) | 0 (0–90) |
Head and Neck | |||||
|  | NEC | 19 | 12 (63%) | 9 (0-230) | 4(0–52) |
Prostate | |||||
|  | AVPC-NEC | 16 | 12 (75%) | 115 (0–250) | 1.5 (0–160) |
AVPC-non-NEC | 10 | 0 (0%) | 0 | 0 | |
Pancreas | |||||
|  | Well-differentiated NET | 135 | 17 (13%) | 0 (0-155) | 0 (0–3) |
Small bowel | |||||
|  | Well-differentiated NET | 52 | 1 (2%) | 0 (0–7) | 0 |
Non-epithelial NET | |||||
|  | Neuroblastoma | 72 | 12 (17%) | 0 (0-160) | 0 (0–20) |
Paraganglioma | 15 | 2 (13%) | 0 (0-17) | 0 (0–7) | |
Pheochromocytoma | 3 | 0 (0%) | 0 | 0 | |
Adrenal gland cortex | |||||
| Â | Adrenocortical carcinoma | 23 | 1 (4%) | 0 (0-15) | 0 (0) |
Adrenocortical adenoma | 11 | 3 (27%) | 0 (0-155) | 0 (0) | |
